Key Points
- Insider sale: Guardant Health director Meghan Joyce sold 10,000 shares on June 3 at an average price of $126.98, totaling about $1.27 million. The sale cut her direct holdings by 47.21%, and it was made under a pre-arranged Rule 10b5-1 plan.
- Stock performance: GH opened at $133.06, near its 52-week high of $134.28, and far above its 52-week low of $40.35. The company now has a market cap of $17.64 billion.
- Analyst sentiment remains positive: Recent coverage from multiple firms includes buy/outperform ratings and price targets as high as $165.00. Overall, Wall Street’s consensus rating is Moderate Buy with an average price target of $137.80.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Meghan Joyce sold 10,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the sale, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. The trade was a 47.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Price Performance
Shares of GH opened at $133.06 on Friday. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $134.28. The stock has a market cap of $17.64 billion, a PE ratio of -39.25 and a beta of 1.61. The firm has a 50-day simple moving average of $98.61 and a two-hundred day simple moving average of $100.91.
Institutional Investors Weigh In On Guardant Health
Large investors have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the fourth quarter worth $27,000. Chesapeake Asset Management LLC purchased a new stake in shares of Guardant Health during the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health during the fourth quarter worth $31,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health during the fourth quarter worth $35,000. Finally, Parallel Advisors LLC increased its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company's stock worth $36,000 after acquiring an additional 219 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
GH has been the topic of several recent analyst reports. Wolfe Research started coverage on shares of Guardant Health in a report on Tuesday. They issued an "outperform" rating and a $150.00 price objective on the stock. BTIG Research set a $160.00 target price on Guardant Health and gave the company a "buy" rating in a research report on Wednesday, May 27th. Canaccord Genuity Group boosted their target price on Guardant Health from $125.00 to $135.00 and gave the company a "buy" rating in a research report on Friday, February 20th. Raymond James Financial reissued an "outperform" rating and issued a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. Finally, The Goldman Sachs Group set a $165.00 target price on Guardant Health and gave the company a "buy" rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $137.80.
View Our Latest Analysis on Guardant Health
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
